Psilocybin Therapy for Depression in Parkinson's Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40-80
SponsorJoshua Woolley, MD, PhD
About this trial
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Eligibility criteria
Qualifiers
Age 40 to 80
Comfortable speaking and writing in English
Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
Currently experiencing depressive symptoms
Disqualifiers
Psychotic symptoms involving loss of insight
Significant cognitive impairment
Regular use of medications that may have problematic interactions with psilocybin
A health condition that makes this study unsafe or unfeasible, determined by study physicians
Trial design
Treatments tested in this trial
- Psilocybin
- Pimavanserin
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Joshua Woolley, MD, PhD
Lead sponsor
University of California, San Francisco
Sponsor institution
Source ClinicalTrials.gov